Clinical research for medical devices has undergone a profound transformation over recent years.
Often perceived as gradual or diffuse, this evolution is nonetheless very real in day-to-day regulatory and clinical practice. Unlike highly visible regulatory milestones such as EUDAMED, this transformation does not stem from a new, headline-grabbing regulation, but rather from the progressive and stringent implementation of Regulation (EU) 2017/745 (MDR) and from the evolving expectations of competent authorities and notified bodies.
This silent transformation is fundamentally reshaping how clinical data are generated, analysed and leveraged throughout the entire lifecycle of medical devices.
Clinical research for medical devices: reinforced requirements across the entire lifecycle
The MDR has profoundly changed the logic of clinical evaluation for clinical research of medical devices.
Where pre-market clinical data were previously sufficient in many cases, the regulation now requires continuous demonstration of safety and clinical performance.
Article 61 of the MDR, together with Annex XIV, places Post-Market Clinical Follow-up (PMCF) at the core of the regulatory system.
Clinical research for medical devices is no longer limited to obtaining CE marking; it becomes a dynamic, ongoing process, fully integrated into the manufacturer’s overall regulatory strategy.
Reference: https://eur-lex.europa.eu/eli/reg/2017/745/2025-01-10
This lifecycle-based approach represents a major cultural shift for manufacturers, who must now consider clinical evidence as a long-term asset, rather than a one-off regulatory deliverable.
PMCF: from regulatory monitoring to genuine clinical research for medical devices
One of the most striking changes concerns the growing importance of PMCF activities.
Initially perceived as a relatively “light” regulatory follow-up, PMCF is increasingly taking the form of structured protocols, closely aligned with classical clinical research methodologies.
In practice, notified bodies now increasingly expect:
- clearly defined clinical objectives,
- methodological justification of study designs,
- documented management of bias and confounding factors,
- full traceability of collected data.
In some cases, studies initially planned as PMCF are reclassified as clinical investigations under the MDR, with significant implications in terms of authorisations, ethics committee involvement and vigilance requirements.
A progressively blurred boundary between clinical studies and clinical investigations
Competent authorities and notified bodies tend to adopt a stricter interpretation of the MDR, leading to:
- reclassification of certain observational studies,
- increased expectations regarding compliance with ISO 14155,
- reinforcement of the role of ethics committees and national competent authorities, such as the ANSM in France.
This evolution requires manufacturers to anticipate very early the regulatory qualification of their clinical projects.
Failure to do so may result in substantial delays, redesign of studies, or additional regulatory procedures.
Real-world data: an opportunity under strict conditions
Real-world data (RWD) and real-world evidence (RWE) are playing an increasingly important role in clinical research for medical devices, particularly within PMCF activities.
They represent a major opportunity to document device use in real-life conditions, especially when randomised clinical investigations are difficult to implement.
However, expectations have significantly evolved.
Notified bodies no longer accept unstructured data derived solely from registries or medico-administrative databases. They now expect:
- formalised study protocols,
- clear data governance frameworks,
- methodological transparency comparable to that required for interventional studies.
RWE therefore becomes a powerful but demanding tool, which must be fully integrated into a coherent and controlled clinical strategy.
Increasing pressure on European attractiveness
This silent transformation also affects the attractiveness of Europe for clinical research on medical devices.
Delays in setting up clinical investigations, administrative complexity, and variability in national practices are frequently cited as barriers.
In this context, quality of clinical dossier preparation, anticipation of regulatory expectations, and mastery of interactions with competent authorities are becoming decisive success factors.
Clinical research for medical devices is no longer assessed solely on scientific merit, but also on regulatory robustness and operational maturity.
Conclusion: a more mature, more demanding clinical research landscape
Clinical research for medical devices has entered a new era.
Without major regulatory announcements, the MDR has deeply transformed practices by reinforcing methodological requirements, continuity of clinical evaluation and the central role of post-market follow-up.
This silent transformation requires medical device stakeholders to raise their level of clinical maturity, fully integrate clinical research into their regulatory strategy, and proactively anticipate the growing expectations of authorities and notified bodies.
Clinical research is no longer a punctual step; it has become a structuring pillar of the medical device lifecycle.
At BluePharm, we support manufacturers, start-ups and institutional stakeholders in this transition toward higher clinical maturity by combining:
- MDR requirements,
- robust clinical research practices,
- structured integration of PMCF and real-world data,
- operational dialogue with competent authorities and notified bodies.
Useful resources
- Clinical Evaluation Guide (GMED)
- Clinical investigations: key differences (ECRIN)
